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INTRODUCTION 
Chronic kidney disease (CKD) is defined as kidney 
damage or estimated glomerular filtration rate (eGFR) 
of less than 60 ml/min/1.73 m2 for a period of 3 months 
or more [1]. End-Stage Renal Disease (ESRD) is the 
final stage of CKD characterized by progressive, 
irreversible deterioration in renal function resulting in 
fluid and electrolyte imbalance. This leads to uremia. 
ESRD is characterized by a decrease in GFR and 
evidence of less than 10% nephron function remaining 
[2]. 
CKD is associated with a variety of hematological 
abnormalities. Anemia is the most common, consistent 
and severe of the various hematological abnormalities
[3]. According to the NKF/KDOQI guidelines (2002), 
anemia in Chronic Kidney Disease can be defined as 
hemoglobin level less than 13.0 g/dl in adult males and 
less than 12.0g/dl in adult females [4]. 
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The primary cause of anemia in CKD patients is 
insufficient production of erythropoietin. Other factors 
include deficiency of iron, folate & B12, probably due 
to increased blood loss or nutritional insufficiency [5]. 
Other causes may consist of acute and chronic 
inflammation with impaired iron utilization, severe 
hyperparathyroidism (HPT) and reduced red cell life 
span due to uremia [5, 6]. 
Prolonged anemia, if untreated, may lead to several 
physiologic disorders. The significant complications 
anticipated are; cardiovascular manifestations like 
decreased tissue oxygenation increased cardiac output, 
ventricular dilatation and ventricular hypertrophy, and 
ultimately increased mortality and morbidity. Renal 
insufficiency is also associated with bleeding tendency 
attributed to platelet dysfunction [5]. 
Besides genetic and pathological factors, certain 
environmental factors may also be responsible for 
development of renal insufficiency. Presently, the 
number of studies on hematological derangements in 
CKD patients is quite less, especially among the Indian 
population [7]. 
The present study was planned to evaluate the 
hematological profile of CKD patients and its 
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comparison with healthy control group at a tertiary care 
center located in the state of Rajasthan. 
MATERIAL AND METHODOLOGY    
Study design: Case-control analytical study  
Ethics approval: The study was conducted after 
seeking approval from the Institutional Ethics 
Committee and informed consent was obtained from all 
participants.  
Sample size: Fifty patients diagnosed for end-stage 
renal disease (ESRD), 
Study population & place: ESRD patients visiting the 
outpatient department of Nephrology at Mahatma 
Gandhi Medical College & Hospital, Jaipur 
Inclusion criteria: Fifty diagnosed cases of CKD (stage 
4 and 5) as per the guidelines of National Kidney 
Foundation [4], age up to 60 years. Fifty age and sex-
matched healthy subjects constituted the control group. 
According to the above criteria, Stage 4 CKD is defined 
as GFR 15 – 29 ml/min/1.73 m2 and Stage 5 CKD is < 
15 ml/min/1.73 m2.  
Exclusion criteria: Patients suffering from primary 
hyperparathyroidism or Vitamin D supplementation, 
who underwent thyroid or parathyroid surgeries, were 
also excluded.  
Methodology: Blood samples were collected for all 
subjects enrolled in the study and subjected to analysis 
for renal function test (RFT) including serum urea, 
creatinine, potassium using dry chemistry and direct ion
-selective electrode method on VITROS 5600 and 
hematological profile including total leucocyte count 
(TLC), hemoglobin (Hb), platelets count and red blood 
cell (RBC) count. 
Statistical analysis: Results obtained were analyzed 
using a statistical package program (SPSS 17 Inc; 
Chicago II, USA) for social science. All variables were 
presented in the two groups as mean ± SD and 
compared by applying Student’s t-test. 
RESULTS  
On the evaluation of distribution of co-morbid 
conditions in CKD patients, the study reported 
hypertension as the most common co-morbid condition 
associated with CKD. Out of fifty CKD patients, 29 
(58%) patients had hypertension, and 4 (8%)had 
Diabetes mellitus.14 patients (28%) patients had both 
hypertension and diabetes mellitus while 3 (6%) 
patients suffered from other comorbidities (Fig 1). 
Parameters evaluated in the study and control group are 
presented in (Table1).The mean Hb level of CKD group 
was as low as 7.50+/- 1.6g/dL. Mean RBC levels were 
significantly lower (P < 0.0001) lower in CKD patients 
(3.03± 0.60) as compared to healthy subjects 
(5.07±0.54). Comparison of Platelets was not 
considerably (221.52± 83) in CKD group as compared 
to healthy subjects (247.73±64.80). The mean serum 
potassium levels were significantly higher in CKD 
population as compared to age-matched healthy subjects 
with normal kidney function (Table 1). 
 
Fig 1. Distribution of the CKD patients based on 
Comorbid Conditions 
Table 1: Distribution of variables between  
CKD patients and Control group 
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Variables 
CKD  
patients 
Control 
t-
value  
P-
value 
Age (years) 38.98±10.3 38.3±13.7 0.29 NS 
Haemoglobin 
(g/dL) 
7.50±1.6 14.7±1.4 -24.02 0.000 
RBC  
(10^6/mm3) 
3.03±0.6 5.1±0.5 -17.87 0.000 
Platelets  
(10^3/uL) 
221.52±83 247.7±65 -1.76 0.081 
Sr. Potassium   
(mmol/L) 
5.98±0.7 4.23±0.5 14.62 0.000 
Table 2: CKD Patients grouped according to severity 
of anemia [8]. 
Type of anemia 
No. of cases 
 (%) 
Mild anemia (10-11.9gm %) 3 (6) 
Moderate anemia (7-9.9gm %) 24 (48) 
Severe anemia (<7gm %) 23 (46) 
Platelet count 
Thrombocytopenia(< 1.5 lakhs/cmm) 6 (12) 
Normal (1.5to 4.5 lakhs/cmm) 42 (84) 
Thrombocytosis (> 4.50 lakhs/cmm) 2 (4) 
Thrombocytopenia (platelet count < 1.50 lakhs/cmm) 
was present in 12% of patients, while thrombocytosis 
(platelet count > 4.50 lakhs/cmm) was present in only 
4% of the total patients. 
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DISCUSSION 
The mean age of CKD patients (38.98 ± 10.32) was 
comparable with that of healthy control group. 
However, out of 50 CKD patients, maximum number 
n=16 (32%) patients were in the group of 51-60 years, 
which is similar to the study done by Ann M et al. [7]. 
The significant comorbidities identified among the CKD 
patients were diabetes and hypertension. The 
observations are similar to the studies carried out by 
Chhetri PK et al.2009[9]and Dash SC et al. 2006[10] 
where diabetes mellitus and hypertension were 
identified as leading causes. Coresh J et al. 2007[11] 
also reported that two leading causes of CKD, i.e. 
hypertension and diabetes, account for as much as 70% 
of all new cases. 
Healthy kidneys produce a hormone called 
erythropoietin (EPO). EPO prompts the bone marrow to 
make red blood cells, which then carry oxygen 
throughout the body [12]. 
Anemia of chronic renal failure is multifactorial. The 
pathogenesis of this type of anemia has been attributed 
to decreased plasma erythropoietin due to renal damage, 
inhibitors of erythropoiesis in uremic plasma, and 
decreased hemoglobin oxygen affinity [13]. In addition 
to damage to renal site of erythropoietin production, 
plasma erythropoietin and erythropoiesis are further 
suppressed in patients with renal disease. The stimulus 
to erythropoietin production is less intense than in 
patients with comparable severe anemia due to other 
causes. This is because the affinity of oxygen decreases, 
which increases the availability of oxygen per unit of 
hemoglobin circulating through the kidney [13]. 
This finding was in concordance with the studies by 
BhattaS et al. [14],Barde R et al. [15], Hakim et al. [12], 
and Bhattacharjee K et al. [16].The prevalence of mild, 
moderate and severe anemia by WHO criteria [6] was 
5.26%, 55.26%, and 39.48% respectively. 
Usually 90%of the hormone is produced in peritubular 
interstitial cells of the kidney and 10% in the liver and 
elsewhere, there are no performed stores and the 
stimulus to erythropoietin production is then oxygen 
tension in the tissues of the kidney, erythropoietin 
production, therefore, increase in anemia, when 
hemoglobin for some reason is unable to give up 
oxygen usually, when atmospheric oxygen is low or 
when destructive cardiac or pulmonary function or 
damage to the renal circulating affect oxygen delivery to 
the kidney. 
Hakim et al. [12] found the mean platelet count among 
ESRD patients to be significantly reduced (1.75+/- 
0.065 lakhs/cmm) compared to controls. Another study 
by Dorgalalehet al.[17] found the mean platelet count in 
CKD patients to be 1.72±0.9 lakhs/ cmm and reduced 
compared to controls. Other studies show platelet 
dysfunction in many cases of ESRD which predisposes 
the patients to bleeding [18,19]. 
CKD and ESRD inevitably lead to K derangements and 
an increased risk of adverse cardiovascular events and 
mortality [20]. Potassium (K) is the most abundant 
intracellular cation with >98% of total body K located 
intracellularly and <2% extracellularly. 
CONCLUSION 
This study showed absolute prevalence of anemia in 
patients of CKD. It was predominantly of the 
normocytic normochromic type, suggesting EPO 
deficiency as the primary cause. However, in some 
cases, the presence of abnormal cells such as 
fragmented RBCs, pencil cells, and macro-ovalocytes 
suggest other contributory factors, such as hemolysis, 
iron deficiency, or folate/vitamin B12 deficiency. 
Neutrophilic leukocytosis in some patients may be 
explained by the tendency towards latent or secondary 
infections. Although the platelet counts, bleeding, and 
clotting times were mostly normal in this study. 
Suggestions: In the light of this study, there is a need 
for nephrologists to monitor the hematological profile of 
CKD patients on dialysis, and treat any derangements in 
the same, to improve outcome for these patients. 
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